BioSpace News Archive

Ever increasing pool of patients with atopic dermatitis, growing investment in research & development for novel drugs and rising awareness will improve sales prospects

Meiji Seika Pharma Co., Ltd. announced that the bioequivalence of DMB-3115, a proposed ustekinumab biosimilar, has been demonstrated in phase I clinical trial compared to the reference products marketed in Europe and the United States.

Evofem Biosciences, Inc. announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock and accompanying two-year warrants to purchase an aggregate of up to 50 million shares of common stock.

Amicus Therapeutics, announced two posters for presentation highlighting its development program for Pompe disease at the 16th International Congress on Neuromuscular Diseases being held virtually, May 21-22 and 28-29, 2021.

Sierra Oncology, Inc., a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted a stock option to a new employee as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan.

Nurix Therapeutics, Inc., a biopharmaceutical company developing targeted protein modulation drugs, announced that preclinical data from its NX-5948 program will be presented at the upcoming European Alliance of Associations for Rheumatology 2021 Virtual Congress, which will be held June 2−5, 2021.

Tislelizumab combined with chemotherapy demonstrated a statistically significant improvement in progression-free survival at the interim analysis

Collaboration aims to develop a next-generation AAV production platform to help accelerate Biogen’s efforts to bring novel gene therapies to patients worldwide Ginkgo’s synthetic biology expertise may enable the expansion of therapeutic utility and overcome development challenges of viral vectors for gene therapy Ginkgo to receive $5 million upfront payment and is eligible for up to $115 million in potential research, development, and commercial milestones

Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the Company will host a webinar highlighting DCCR (diazoxide choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS) at the 23 rd European Congress of Endocrinology 2021, on Monday, May 24, 2021, at 8:15 AM Central European Summer Time